The latest update is out from Repligen ( (RGEN) ).
The Company has issued a supplemental slide presentation to shed light on a recent Restatement and its effects on financials, emphasizing that there is no impact on overall business operations or strategic outlook. This follows a review prompted by the PCAOB’s inspection, leading to a restatement of the financials for 2023 and the first half of 2024 due to a timing change in recognizing a COVID-related cancellation fee. Despite this, the Company maintains its full-year 2024 revenue guidance, adjusting for the $6.6M now allocated to the first half of the year. They also highlight non-GAAP measures, excluding various costs to better represent ongoing operations, and caution against relying solely on these when analyzing the Company’s performance.
For detailed information about RGEN stock, go to TipRanks’ Stock Analysis page.
